Utah Medical Products Inc (UTMD)

Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2026April 23, 2026 9:00 AM
ACCESS NewswireSALT LAKE CITY, UT / ACCESS Newswire / April 23, 2026 / In the first calendar quarter (1Q) of 2026, Utah Medical Products, Inc. (Nasdaq:UTMD) attained financial results which were consistent with its previously announced projections for calendar year 2026. But because of the relatively short span of time, results for any given three-month period in comparison with a previous three-month period may not be indicative of comparative results for the year as a whole.Summary of results.
The following is a summary comparison of 1Q 2026 with 1Q 2025 income statement measures:Revenues (Sales): (10.2%) Gross Profit (GP): ( 4.6%) Operating Income (OI): (18.7%) Net Income (NI): (14.4%) Earnings Per Share (EPS): (11.0%) Profit margins in 1Q 2026 compared to 1Q 2025 follow: 1Q 2025 1Q 2024 1Q 2026
(JAN - MAR) 1Q 2025
JAN - MAR Gross Profit Margin (gross profits/ sales): 60.6% 57.0%Operating Income Margin (operating income/ sales): 29.4% 32.5%EBT Margin (profits before income taxes/ sales): 36.5% 39.7%Net Income Margin (profit after taxes/ sales): 29.9% 31.3% Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € or EUR = Euros. Currency amounts throughout this report are in thousands, except per share amounts and where noted.Consolidated sales in 1Q 2026 were $987 lower than in 1Q 2025. As expected and previously reported, UTMD did not have any 1Q 2026 sales to its previous largest medical device distributor of blood pressure monitoring kits in China, or to its previous OEM customer, PendoTECH. The combined sales to those two entities in 1Q 2025 were $857, representing 87% of the lower 1Q 2026 sales. Although overall domestic sales were about the same in both 1Q 2026 and 2025, sales outside the U.S. (OUS) excluding the China distributor were another $176 lower, due to lower Filshie Clip System sales OUS.Using the same foreign currency exchange (FX) rates for sales not invoiced in USD, i.e. in "constant currency" terms, OUS sales would have been an additional $169 lower because of a weaker USD. FX rates for income statement purposes are transaction-weighted averages.The average FX rates from the applicable foreign currency to USD during 1Q 2026 and 1Q 2025 follow:
1Q 2026 1Q 2025 Change GBP 1.348 1.261 +6.9%EUR 1.165 1.073 +8.5%AUD 0.698 0.628 +11.1%CAD 0.730 0.697 +4.7%UTMD's 1Q 2026 GP at $5,282 was $256 lower than 1Q 2025 GP of $5,538. The 4.6% lower GP was less than the 10.2% decline in sales as a result of a more favorable product mix and a yearly one-time adjustment to standard costs which increased inventory value. Historically, sales to UTMD's largest OUS distributor in China had a significantly lower GP Margin (GPM), GP/Revenues, than UTMD's average GPM. Although manufacturing overhead costs were higher, which should lower the GPM when sales are lower, UTMD continues to effectively manage its variable manufacturing expenses.Consolidated worldwide (WW) OI, which is GP less Operating Expense (OE), in 1Q 2026 at $2,565 (29.4% of sales) was $588 lower than 1Q 2025 OI of $3,154 (32.5% of sales). OI was $332 lower in addition to the $256 lower GP, due to $127 higher litigation expenses, $147 higher employee health care costs in U.S. General and Administrative (G&A) expense and $65 higher same foreign currency exchange rate of OUS OE due to a weaker USD. In the aggregate, the components of WW OE in USD terms were Product Development (R&D) expenses about the same, Sales & Marketing (S&M) expenses $19 higher and G&A expenses $314 higher than in 1Q 2025, respectively.Income Before Tax (EBT) declined more than the $588 lower OI because net non-operating income (NOI) in 1Q 2026 was just $617 compared to $705 in 1Q 2025. The lower NOI was due to lower interest earned on cash balances. Combining the $588 lower OI with the about $89 lower NOI yielded 1Q 2026 EBT $677 (17.5%) lower than in 1Q 2025. UTMD's EBT Margin (EBT/sales) was 36.5% in 1Q 2026 compared to 39.7% in 1Q 2025.UTMD's consolidated income tax provision rate in 1Q 2026 was 18.2% compared to 21.2% in 1Q 2025. An EBT mix difference among subsidiary sovereignties caused the provision rate difference. The basic corporate income tax rate for the U.S. (including Utah state income tax) is 25.45% and for Ireland on EBT from exports is 12.5%. The lower income tax provision rate offset the 17.5% lower EBT, resulting in 1Q 2026 NI that was 14.4% lower than in 1Q 2025. Fewer outstanding shares as a result of UTMD's share repurchases further reduced the decline in 1Q 2026 earnings per share (EPS), which is NI/diluted number of outstanding shares, to be just 11.0% lower than in 1Q 2025. During the four calendar quarters following the end of 1Q 2025, UTMD repurchased 96,864 of its shares in the open market. There was no dilution from outstanding employee stock options for purposes of calculating diluted EPS in either 1Q 2026 or 1Q 2025. In income statement summary, with the top line declining 10.5% in 1Q 2026 compared to 1Q 2025, EPS declined 11.0%.UTMD's March 31, 2026 Balance Sheet, in the absence of debt, remained strong. After using $9.5 million in cash during the most recent twelve-month period to make share repurchases, pay stockholder dividends and purchase new equipment, UTMD's March 31, 2026 cash equivalent balances were $4.1 million higher than at March 31, 2025. Ending 1Q 2026 cash equivalent balances were about $1.7 million higher than three months earlier at December 31, 2025. Stockholders' Equity (SE) at $120.4 million improved $1.1 million at the end of 1Q 2026 from three months earlier, despite the fact that dividends and share repurchases reduce SE.FX rates for Balance Sheet purposes are the applicable rates at the end of each reporting period. The FX rates from the applicable foreign currency to USD for assets and liabilities at the end of 1Q 2026 and the end of 1Q 2025 follow:
3-31-26 3-31-25 Change GBP 1.318 1.289 2.3%EUR 1.152 1.079 6.7%AUD 0.685 0.624 9.9%CAD 0.717 0.695 3.0%Sales.Total consolidated 1Q 2026 UTMD sales were $987 (10.2%) lower than in 1Q 2025. Constant currency sales were $1,156 (11.9%) lower. U.S. domestic sales were 0.4% lower, and OUS sales were 23.4% lower.Domestic sales in 1Q 2026 were almost the same at $5,560 compared to $5,583 in 1Q 2025. The components of domestic sales include 1) "direct sales" of UTMD's medical devices to user facilities (and med/surg stocking distributors for hospitals), excluding Filshie device sales, 2) "OEM sales" of components and other products manufactured by UTMD for other medical device and non-medical device companies, and 3) "Filshie device sales", manufactured by Femcare and distributed in the U.S. by UTMD.Direct medical device sales, representing 61% of total domestic sales, were $503 (12.8%) lower in 1Q 2026 than in 1Q 2025. Sales were lower in all product categories in what was hopefully just an abnormally weak demand quarter.Total domestic OEM sales in 1Q 2026, representing 11% of all domestic sales, were $13 (2.1%) lower than in 1Q 2025, as the final $69 order backlog to PendoTECH was shipped in 1Q 2025.Domestic Filshie device sales, representing 28% of all domestic sales, were $493 (+47.4%) higher in 1Q 2026 compared to 1Q 2025, which appears to be an abnormally high U.S. medical facility demand quarter.OUS sales in 1Q 2026 were $965 (23.4%) lower at $3,162 compared to $4,127 in 1Q 2025. Sales to UTMD's former distributor in China which were $789 in 1Q 2025 (and zero in 1Q 2026), which explains 82% of the $965 lower OUS sales. Although Filshie device sales directly to medical facilities in Ireland and the UK were about the same in both periods, direct Filshie device sales to medical facilities in Canada, France and Australia were $230 lower. OUS foreign currency sales actually benefited $169 from a weaker USD. On a constant currency basis, 1Q 2026 OUS sales were $1,133 (27.5%) lower than in 1Q 2025. OUS sales invoiced in foreign currencies in 1Q 2026 were $2,327, which was 74% of all OUS sales, and 27% of total 1Q 2026 UTMD consolidated sales. Foreign currency OUS sales in 1Q 2025 were $2,944, which was 71% of all OUS sales and 30% of total 1Q 2025 UTMD consolidated sales.Gross Profit (GP).UTMD's 1Q 2026 GP was $256 (4.6%) lower in 1Q 2026 than in 1Q 2025, driven by 10.2% lower sales. GP results from subtracting the costs of manufacturing products, including direct labor, raw materials and manufacturing overhead (MOH) expenses, from revenues. MOH, which was higher due primarily to cost-of-living adjustments for employees, includes supervision, engineering, quality assurance, outside services, depreciation of manufacturing equipment, purchasing and freight for receiving raw materials from vendors. Higher MOH expense with lower sales decreases the GPM. Nevertheless, UTMD's average GPM in 1Q 2026 was 60.6% compared to 57.0% in 1Q 2025. Although the lack of low GPM sales to UTMD's former China distributor helped to improve the average GPM, the margin increase was further leveraged by an annual standard cost adjustment after the end of 2025, which increased the book value of inventories. As a side note, UTMD in the U.S. distributes Filshie devices direct to U.S. medical facilities, which are manufactured by its Ireland subsidiary. Tariffs paid to the U.S. government on Filshie devices purchased from UTMD's own subsidiary "off the top" of intercompany sales were $108 higher in 1Q 2026 compared to 1Q 2025. This had the equivalent financial effect of raising UTMD's federal income tax rate in the U.S., thus lowering consolidated net income and EPS, which does not increase UTMD U.S. stockholder value to be sure.Operating Income (OI).OI results from subtracting Operating Expenses (OE) from GP. OI of $2,565 in 1Q 2026 was $588 (18.7%) lower than the $3,154 OI in 1Q 2025. OE is comprised of G&A expenses, S&M expenses and R&D expenses. Consolidated OE were $2,717 in 1Q 2026 (31.1% of sales) compared to $2,385 in 1Q 2025 (24.6% of sales). The substantial $332 increase in 1Q 2026 OE came predominantly from a $314 increase in 1Q 2026 G&A expenses.Consolidated G&A expenses were $2,044 (23.4% of sales) in 1Q 2026 compared to $1,730 (17.8% of sales) in 1Q 2025. The $314 increase in G&A expenses came from three causes: 1) U.S. G&A employee health care cost, 2) litigation expense, and 3) the effect of a weaker USD when translating foreign currency subsidiary G&A expenses. Net other G&A expenses were slightly lower.UTMD in the U.S. self-insures its health care plan, where costs are typically driven by a small portion of employees when a major claim occurs. U.S. G&A heath care costs were $147 higher in 1Q 2026 than in 1Q 2025. Although not predictable, UTMD expects the remainder of year 2026 experience should be more like 2025.Although UTMD has now won 15 of 19 court case dismissals, a confluence of litigation deadlines in 1Q 2026 necessitated significant legal work in the remaining few. Although litigation expense in 1Q 2026 was $127 higher than in 1Q 2025, UTMD continues to expect litigation expense for the 2026 year will be less than for the 2025 year. This of course assumes that, as has been the experience so far, no case goes to trial.Constant currency G&A expenses of foreign subsidiaries were $56 higher due to a weaker USD in 1Q 2026 compared to 1Q 2025. A $29 portion of that $56 was due to translation of identifiable intangible asset (IIA) amortization expense resulting from the 2011 Femcare acquisition, which was completed in 1Q 2026. As a side note, the 1Q 2026 IIA amortization expense, which will be zero in ensuing 2026 quarters, was $458.S&M expenses were $519 (5.9% of sales) in 1Q 2026 compared to $500 (5.1% of sales) in 1Q 2025. The change in FX rates increased 1Q 2026 OUS S&M expenses by $9. The remaining increase was due to increases in S&M salaries. Consequently, more than half of higher S&M expense percentage of sales was due to lower sales.R&D expenses in 1Q 2026 were $154 (1.8% of sales) compared to $155 (1.6% of sales) in 1Q 2025. There were no OUS R&D expenses.Income Before Tax (EBT).EBT results from subtracting net non-operating expense (NOE) or adding net non-operating income (NOI) from or to, as applicable, OI. Consolidated 1Q 2026 EBT was $3,181 (36.5% of sales) compared to $3,859 (39.73% of sales) in 1Q 2025. The $677 (17.5%) lower 1Q 2026 EBT compared to 1Q 2025 was the result of $588 lower OI combined with $89 lower NOI. NOE/NOI includes the combination of 1) expenses from loan interest and bank fees; 2) expenses or income from losses or gains from remeasuring the value of EUR cash bank balances in the UK, and GBP cash balances in Ireland, in USD terms; and 3) income from rent of underutilized property, investment income and royalties received from licensing the Company's technology. NOI in 1Q 2026 included $106 lower interest income on UTMD's cash balances.The EBT of Utah Medical Products, Inc. in the U.S. was $2,825 in 1Q 2026 compared to $3,546 in 1Q 2025. The EBT of Utah Medical Products, Ltd (Ireland) was EUR 1,164 in 1Q 2026 compared to EUR 1,393 in 1Q 2025. The EBT of Femcare Group Ltd (Femcare Ltd., UK and Femcare Australia Pty Ltd) was GBP (686) in 1Q 2026 compared to GBP (663) in 1Q 2025. The 1Q 2026 EBT of Utah Medical Products Canada, Inc. was CAD (37) compared to CAD 107 in 1Q 2025. The differences in the U.S. and UK EBT were accentuated by intercompany transfer of litigation expenses which did not affect consolidated results.Excluding the noncash effects of depreciation, amortization of intangible assets and stock option expense, 1Q 2026 consolidated EBT excluding the remeasured bank balance currency gain or loss and interest expense ("adjusted consolidated EBITDA") were $3,982 compared to $4,652 in 1Q 2025. UTMD's trailing twelve-month EBITDA as of March 31, 2026 was $16,788.Net Income (NI).NI in 1Q 2026 of $2,604 was $438 (14.4%) lower than the NI of $3,041 in 1Q 2025. UTMD's NI Margin, NI divided by consolidated sales, was 29.9% in 1Q 2026 and 31.3% in 1Q 2025. The smaller 14.4% NI decline compared to 17.5% lower EBT was due to average consolidated income tax provision rates (as a % of EBT) in 1Q 2026 of 18.2% and 21.2% in 1Q 2025. Although basic corporate income tax rates did not change, the consolidated income tax provision can vary from period-to-period depending on the portion of EBT in sovereignties with differing rates, and a periodic true-up when actual tax returns are filed.Earnings per share (EPS).EPS in 1Q 2026 at $0.818 were 11.0% lower than the $0.919 in 1Q 2025. UTMD's smaller decline in EPS relative to NI was a result of 125,265 fewer diluted shares used to calculate EPS in 1Q 2026 compared to 1Q 2025. Diluted shares were 3,184,983 in 1Q 2026 compared to 3,310,248 in 1Q 2025. Outstanding shares were 3,184,025 at the end of 1Q 2026. The number of shares used for calculating EPS was higher than ending shares because of a time-weighted calculation of average outstanding shares for shares which were repurchased during the quarter. There was no dilution from unexercised employee options in either 1Q 2026 or 1Q 2025 as the average option exercise prices were above the period-ending closing stock prices. The total number of outstanding unexercised employee and outside director options at March 31, 2026 was 121,085 at an average exercise price of $70.66, including shares awarded but not yet vested. This compares to 97,779 unexercised option shares at the end of 1Q 2025 at an average exercise price of $73.77/ share, including shares awarded but not vested.Outstanding shares at the end of 1Q 2026 were 3,184,025 compared to 3,186,221 at the end of calendar year 2025 and 3,280,889 at the end of 1Q 2025. The difference in outstanding shares at the end of 1Q 2026 compared to the end of 2025 resulted from 2,196 shares repurchased in the open market, with no employee options exercised, during 1Q 2026.UTMD repurchased 2,196 of its shares at an average price of $58.58 during 1Q 2026. Because of a time-weighted calculation, the full antidilution impact of the 1Q 2026 repurchases won't be felt until 2Q 2026. There were 54,267 share repurchases in 1Q 2025 at an average price of $59.35. No options were awarded in 1Q 2026 or 1Q 2025. During the rest of 2025 after 1Q 2025, 13,800 option shares were awarded to 40 employees at an exercise price of $58.10. The Company retains the strong desire and financial ability for repurchasing its shares at a price it believes is attractive for remaining stockholders. UTMD's closing share price at the end of 1Q 2026 was $61.99, up 11% from the $55.96 closing price three months earlier at the end of 2025. The closing share price at the end of 1Q 2025 was $56.04.UTMD paid $989 ($0.31/share) in cash dividends to stockholders in 1Q 2026. UTMD paid $1,017 ($0.305/share) in cash dividends to stockholders in 1Q 2025.Balance Sheet.At March 31, 2026 compared to three months earlier at the end of 2025, UTMD's cash and investments increased $1,649 to $87,406, despite use of $129 cash to repurchase shares, pay $989 in stockholder dividends and purchase $130 in additional capital equipment. Compared to a year earlier at March 31, 2025, cash and investments increased $4,081. At March 31, 2026, net Intangible Assets declined $610 to 11.5% of total consolidated assets from 12.2% on December 31, 2025. The decline in Net Intangible Assets from a year earlier was $1,893. Inventories increased $787 from the end of 2025, and $75 from a year earlier. Working capital at the end of 1Q 2026 was $1,730 higher than at the end of 2025, and $4,798 higher than at March 31, 2025. UTMD's current ratio improved to 28.6 at March 31, 2026 from 22.3 at March 31, 2025. The current ratio at the end of 2025 was 37.6 due to low end-of-year current liabilities. Consolidated Accounts Receivable (net of allowances) increased $115 at March 31, 2026 from the end of 2025, but decreased $307 compared to March 31, 2025 due to lower sales. On a rolling sales quarter basis, the aging of receivables were 37.5 days at the end of 1Q 2026, compared to 35.0 days at the end of 2025 and 36.6 days at the end of March 2025, all well within management targets.As of March 31, 2026, Stockholders' Equity (SE) increased $3,325 to $120,373 compared to a year earlier at March 31, 2025, despite a reduction in SE from the $9,218 combination of share repurchases and stockholder cash dividends paid during the last twelve months. During 1Q 2026, SE increased $1,105 from the end of 2025 while the company paid $989 in dividends and repurchased $129 in stock, which reduced SE.Financial ratios as of March 31, 2026 which may be of interest to stockholders follow:Current Ratio = 28.6Days in Trade Receivables (based on 1Q 2026 sales activity) = 37.5Average Inventory Turns (based on 1Q 2026 CGS) = 1.72026 YTD ROE (before dividends) = 8.7%Investors are cautioned that this press release contains forward looking statements and that actual events may differ from those projected. Risk factors that could cause results to differ materially from those projected include global economic conditions and potential trade wars, market acceptance of products, regulatory approvals of products, regulatory intervention in current operations, government intervention in healthcare and the economy in general, tax reforms, the Company's ability to efficiently manufacture, market and sell products, cybersecurity and foreign currency exchange rates, among other factors that have been and will be outlined in UTMD's public disclosure filings with the SEC.Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in over one hundred countries around the world as the standard for obtaining optimal long-term outcomes for their patients. For more information about Utah Medical Products, Inc., visit UTMD's website at www.utahmed.com.Utah Medical Products, Inc.INCOME STATEMENT, First Quarter ended March 31
(in thousands except Earnings Per Share)
1Q 2026 1Q 2025 Percent Change Net Sales $8,722 $9,710 (10.2%)Gross Profit 5,282 5,538 (4.6%)Operating Income 2,565 3,154 (18.7%)Income Before Tax 3,182 3,859 (17.5%)Net Income 2,604 3,041 (14.4%)Earnings Per Share $0.818 $0.919 (11.0%)Shares Outstanding (diluted) 3,185 3,310 BALANCE SHEET(in thousands) (unaudited)MAR 31, 2026 (audited)DEC 31, 2025 (unaudited)MAR 31, 2025 Assets


Cash & Investments $87,406 $85,756 $83,325 Accounts & Other Receivables, Net 3,636 3,522 3,944 Inventories 8,722 7,935 8,647 Other Current Assets 614 529 483 Total Current Assets 100,378 97,742 96,399 Property & Equipment, Net 9,721 9,908 9,945 Intangible Assets, Net 14,283 14,892 16,175 Total Assets $124,382 $122,542 $122,519 Liabilities & Stockholders' EquityAccounts PayableREPAT Tax PayableOther Accrued Liabilities 1,194-2,311 911-1,687 9146982,712 Total Current Liabilities 3,505 2,598 4,324 Deferred Tax Liability - Intangible AssetsLong Term Lease LiabilityDeferred Revenue and Income Taxes -210294 114225337 493269386 Stockholders' Equity 120,373 119,268 117,047 Total Liabilities & Stockholders' Equity $124,382 $122,542 $122,519 Contact:Brian Koopman
(801) 566-1200SOURCE: Utah Medical Products, Inc.View the original press release on ACCESS NewswireOriginal: Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2026

This one especially hurts as I’m seeing close friends struggle with fertility.

Dr. James Thorp found that the vaccine causes miscarriage, stillbirth, birth defects, and even death of the newborn.

Also, an animal study found the vaccine DESTROYS 60% of the ovarian reserve. pic.twitter.com/109ejSfdeN— Anna Matson (@AnnaRMatson) May 22, 2025 $UTMD

Utah Medical Products, Inc. Announces Quarterly Dividend

SALT LAKE CITY, UT / ACCESSWIRE / July 30, 2015 / Utah Medical Products, Inc. (NASDAQ: UTMD) announces that its Board of Directors approved a quarterly cash dividend of twenty-five and a half cents ($.255) per share of common stock payable on October 2, 2015 to shareholders of record at the close of business on September 18, 2015. This is a 2% increase over the dividend declared in the same quarter of the prior year.

Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in hundreds of countries around the world as the standard for obtaining optimal long term outcomes for their patients. For more information about Utah Medical Products, Inc., visit UTMD's website at www.utahmed.com.

Contact:

Paul Richins
(801) 566-1200

SOURCE: Utah Medical Products, Inc.
https://www.accesswire.com/430946/Utah-Medical-Products-Inc-Announces-Quarterly-Dividend

Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2015
Marketwired
Utah Medical Products, Inc.
April 23, 2015 9:00 AM


SALT LAKE CITY, UT--(Marketwired - Apr 23, 2015) - In the first calendar quarter (1Q) of 2015, Utah Medical Products, Inc. (NASDAQ: UTMD) achieved results representing a solid start to meeting its previously announced goals for 2015, despite significant foreign currency exchange (FX) rate headwinds. The headwinds in U.S. Dollar terms reduced consolidated sales and had a leveraged negative effect on profits.

The following is a summary comparison of 1Q 2015 with 1Q 2014 income statement measures:


Sales: +4%
Gross Profit: +1%
Operating Income: +1%
Net Income: (2%)
Earnings Per Share: (2%)


As UTMD states in its quarterly SEC Form 10-Q disclosures, 'Because of the relatively short span of time, results for any given three month period in comparison with any previous three month period may not be indicative of comparative results for the year as a whole.'

Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; GBP = UK Pound Sterling; and Euro = Euros. Currency amounts throughout this report are in thousands, except per share amounts and where noted.

UTMD's FX rates for income statement purposes are transaction-weighted averages. The average rates from the applicable foreign currency to USD during 1Q 2015 and 1Q 2014 follow:


1Q 2015 1Q 2014 Change
GBP 1.514 1.655 (8.5%)
Euro 1.119 1.372 (18.5%)
AUD 0.784 0.899 (12.8%)


UTMD's FX rates for balance sheet purposes are the applicable rates at the end of each reporting period. The FX rates from the applicable foreign currency to USD for assets and liabilities at the end of 1Q 2015 and the end of 1Q 2014 follow:


1Q 2015 1Q 2014 Change
GBP 1.485 1.667 (11.0%)
Euro 1.074 1.377 (22.0%)
AUD 0.763 0.927 (17.8%)


UTMD's profit margins remained strong despite the negative FX on about one-third of sales:


1Q 2015
(JAN - MAR) 1Q 2014
(JAN - MAR)
Gross Profit Margin (gross profits/ sales): 59.7% 61.6%
Operating Profit Margin (operating profits/ sales): 37.9% 39.1%
EBT Margin (profits before income taxes/ sales): 35.8% 38.5%
Net Profit Margin (profit after taxes/ sales): 26.1% 27.7%


Sales.
Total consolidated 1Q 2015 UTMD sales were $406 higher than in 1Q 2014 (up 4%). In brief, comparing 1Q 2015 to 1Q 2014, U.S. domestic sales were much stronger and UK domestic GBP sales were much weaker, further leveraged down in USD terms by a stronger USD. Approximately one-third of UTMD's sales are invoiced in foreign currencies. If 1Q 2015 foreign currency sales were converted to USD at the same FX rates as in 1Q 2014, 1Q 2015 total consolidated sales would have been an additional $397 higher, or up 8% overall compared to 1Q 2014.

Total international sales in 1Q 2015 were $130 lower (3%) than in 1Q 2014 because of the weaker foreign currencies. Using 1Q 2014 FX rates, 1Q 2015 international sales would have been $267 higher (+5%) rather than $130 lower. As a result of the FX rate changes, international sales were only 47% of total consolidated sales compared to 51% in 1Q 2014. International sales exported from the U.S. in fixed USD terms were up 16%, while international sales by UTMD's foreign subsidiaries converted to USD terms were down 9%. International sales by UTMD foreign subsidiaries in USD terms using the same FX rates as in 2014 would have been up 2% rather than down 9%.

Trade sales are sales to third parties, excluding sales from one UTMD entity to another. Ireland subsidiary 1Q 2015 trade sales were up $547 (+91%). The large increase resulted from $342 sales of blood pressure monitoring (BPM) kits to UTMD's China distributor, and $387 in shipments of Filshie Sterishot kits, now manufactured by UTMD Ireland, directly to international customers located outside the UK, neither of which occurred in 1Q 2014 Ireland trade sales. Although Ireland domestic sales were up 9% in Euro terms, they were down 11% in USD terms because of the weaker Euro.

Trade sales by UTMD's UK subsidiary, Femcare-Nikomed Ltd, were down overall by $493 (14% lower). Sales of Sterishot kits to international customers outside the UK which were included in UK sales in 1Q 2014 were shipped directly from Ireland in 1Q 2015. UK domestic sales were down $236 (22% lower) in part due to the 9% weaker GBP, and sales to Femcare's U.S. distributor of the Filshie Clip System (which are included in the U.S. domestic sales category) were up $270 (22% higher).

Sales by UTMD's Australia subsidiary, Femcare Australia Pty Ltd, in 1Q 2015 were 5% lower in AUD terms than in 1Q 2014, but because of the weaker AUD, were down $121 (17% lower) in USD.

U.S. domestic sales were up $536 (11% higher) in 1Q 2015 compared to 1Q 2014. Direct sales of devices to U.S. user facilities were up $115 (4% higher). In addition to Filshie Clip System sales to its U.S. distributor up $270 (22% higher), UTMD's sales of components and finished devices to other U.S. companies for use in their products (OEM customers) were up $150 (31% higher).

Gross Profit.
UTMD's gross profit margin (GPM), gross profits divided by consolidated sales, at 61.6% in 1Q 2014 was higher than for the full year of 2014 at 60.5%. With a stronger USD, the consolidated GPM is squeezed, assuming that unit prices invoiced in foreign currencies are kept constant, because raw materials and finished devices sold to UTMD's foreign subsidiaries in fixed USD increase the cost of goods sold by the foreign subsidiary. In addition, 1Q 2015 product mix was less favorable than 1Q 2014. BPM kits sales to UTMD's China distributor, at a low GPM, were 3.3% of total consolidated sales in 1Q 2015 compared to none in 1Q 2014. Given the substantially lower FX rates and less favorable product mix, the 1Q 2015 GPM of 59.7% was better than expected.

Operating Income.
Operating expenses, comprised of general and administrative (G&A), sales and marketing (S&M) and product development (R&D) expenses, were $2,235 in 1Q 2015 (21.8% of sales) compared to $2,207 in 1Q 2014 (22.5% of sales). The lower ratio of operating expenses to sales was due to about the same consolidated USD expenses with higher consolidated sales. In this case, the lower FX rates were helpful, as 1Q 2015 operating expenses of UTMD's foreign subsidiaries in the aggregate would have been $115 higher using 1Q 2014 FX rates.

Consolidated G&A expenses were $1,507 (14.7% of sales) in 1Q 2015 compared to $1,542 (15.7% of sales) in 1Q 2014. The G&A expenses in 1Q 2015 included $611 (6.0% of sales) of non-cash expense from the amortization of identifiable intangible assets resulting from the Femcare acquisition, which were $668 (6.8% of sales) in 1Q 2014. The lower USD amortization expense was the result of a stronger USD, as the amortization expense was GBP 404 in both periods.

S&M expenses were $573 (5.6% of sales) in 1Q 2015 compared to $542 (5.5% of sales) in 1Q 2014. S&M expenses in 1Q 2015 included $68 MDET, $2 higher than in 1Q 2014 due to higher U.S. domestic sales of medical devices. The U.S. Medical Device Excise Tax (MDET), imposed as a component of the Patient Protection and Affordable Care Act (Obamacare), is levied as 2.3% of domestic sales of medical devices.

R&D expenses were $156 (1.5% of sales) compared to $123 (1.2% of sales) in 1Q 2014.

Operating income in 1Q 2015 was $3,877 compared to $3,843 in 1Q 2014 (0.9% higher), despite a GPM that was 1.8 percentage points lower than in the previous year's 1Q period. UTMD's 1Q 2015 operating profit margin (OPM), operating income divided by sales, was 37.9% compared to 39.1% in 1Q 2014.

Income Before Tax.
Income before taxes (EBT) results from subtracting net non-operating expense (NOE) from operating income. Consolidated 1Q 2015 EBT was $3,668 compared to $3,782 in 1Q 2014. The $114 lower EBT can be attributed to a $177 loss on the remeasured value of Euro cash balances in the UK, which dropped by more than 11% in value relative to the USD at the end of 1Q 2015 from the end of 4Q 2014. Consolidated UTMD EBT margins (EBT divided by sales) were 35.8% in 1Q 2015 compared to 38.5% in 1Q 2014. The lower EBT margin is due to the lower GPM and the remeasured currency loss.

NOE includes 1) loan interest, 2) bank fees and 3) losses from remeasuring the value of Euro cash bank balances in the UK, and GBP cash balances in Ireland, in USD terms, minus non-operating income from 1) rent of underutilized property, 2) investment income and 3) royalties received from licensing the Company's technology. Net NOE in 1Q 2015 was $209 compared to $61 in 1Q 2014. The total loss on remeasured foreign currency balances in 1Q 2015 was $168 compared to none in 1Q 2014. The loans obtained to help finance the acquisition of Femcare in 1Q 2011 were fully repaid in 1Q 2015 at an expense of $65 including accrued interest and bank fees. Looking forward to the remainder of 2015, this portion of NOE will be zero. In 1Q 2014, the interest expense on bank debt was $87.

The EBT of Utah Medical Products, Ltd (Ireland) was Euro 751 in 1Q 2015 compared to Euro 88 in 1Q 2014. The EBT of Femcare Group Ltd (Femcare-Nikomed, Ltd., UK and Femcare Australia) was GBP 945 in 1Q 2015 compared to GBP 1,159 in 1Q 2014. The respective EBT margins of UTMD Ltd. (Ireland) were 43.5% in 1Q 2015 and 18.6% in 1Q 2014, and of Femcare Group were 37.6% in 1Q 2015 and 41.2% in 1Q 2014.

Excluding the noncash effects of depreciation, amortization of intangible assets and stock option expense, 1Q 2015 consolidated EBT excluding the remeasured bank balance currency loss and interest expense ("adjusted consolidated EBITDA") were $4,698, about the same as the $4,713 consolidated EBITDA in 1Q 2014 despite the significant FX headwinds. Management believes that this operating performance provides a good start to achieving its financial objectives for the year 2015, as previously provided in its 2014 SEC 10-K Report.

Net Income.
Net Income in 1Q 2015 of $2,667 was also close to the net income of $2,722 in 1Q 2014, despite the impact of FX rates on sales and GPM, and the remeasured foreign currency loss. UTMD's net profit margin (NPM), net income divided by consolidated sales, was 26.1% in 1Q 2015 and 27.7% in 1Q 2014. The average consolidated income tax provisions (as a % of EBT) in 1Q 2015 and 1Q 2014 were 27.3% and 28.0%, respectively.

UTMD's combined state and federal income tax provision rate in the U.S. after all allowable deductions was 34.2% in 1Q 2015 compared to 33.9% in 1Q 2014. The corporate income tax rate in the UK was 21% in 1Q 2015 compared to 23% in 1Q 2014. As of April 1, 2015, the UK corporate tax rate will be reduced again, from 21% to 20%, which will further benefit UTMD's NPM during the remainder of 2015. The income tax rate in Australia remained 30% in both periods. The UTMD Ltd (Ireland) tax rate on export profits remains 12.5%.

Earnings per share (EPS).
EPS in 1Q 2015 were about one cent lower than in 1Q 2014. Earnings per share for the most recent twelve months were $3.00. Diluted shares used to calculate EPS decreased to 3,776,400 in 1Q 2015 from 3,786,700 in 1Q 2014 despite a higher average share price and employee option exercises which are factors that increase dilution, as a result of 22,200 shares repurchased after the end of 1Q 2014. The number of shares added as a dilution factor in 1Q 2015 was 26,100 compared to 37,000 in 1Q 2014.

Outstanding shares at the end of 1Q 2015 were 3,752,600. The number of shares used for calculating earnings per share was higher than ending shares because of a time-weighted calculation of average outstanding shares plus dilution from unexercised employee and director options. The total number of outstanding unexercised employee and outside director options at March 31, 2015 was 83,900 shares at an average exercise price of $37.29/ share, including shares awarded but not vested. This compares to 74,900 unexercised option shares outstanding at March 31, 2014 at an average exercise price of $27.94/ share.

During both 1Q 2015 and 1Q 2014, UTMD did not repurchase its shares in the open market. The Company retains the financial ability for repurchasing its shares when they seem undervalued. The closing share price at the end of 1Q 2015 was $59.86 compared to $60.05 at the end of calendar year 2014, and $57.83 at the end of 1Q 2014.

Balance Sheet.
As of March 31, 2015, UTMD is debt free, four years after borrowing $26.9 million to help finance the acquisition of Femcare Group, Ltd. Compared to a year earlier, in addition to paying off $8.1 million of debt, cash and investments increased $1.1 million to $16.2 million, and Stockholders' Equity increased $0.9 million after cash payments of dividends to shareholders of $3.8 million (which reduce Stockholders' Equity). At March 31, 2015, net Intangible Assets were 54.2% of total consolidated assets compared to 57.5% a year earlier.

Foreign subsidiary assets and liabilities, when consolidated in USD terms, were reduced 11%-22% compared to a year ago, according to the table above.

Financial ratios as of March 31, 2015 which may be of interest to shareholders follow:
1) Current Ratio = 5.0
2) Days in Trade Receivables (based on 1Q 2015 sales activity) = 37
3) Average Inventory Turns (based on 1Q 2015 CGS) = 3.4
4) 2015 YTD ROE (before dividends) = 17%

Investors are cautioned that this press release contains forward looking statements and that actual events may differ from those projected. Risk factors that could cause results to differ materially from those projected include market acceptance of products, timing of regulatory approval of new products, regulatory intervention in current operations, government healthcare "reforms", the Company's ability to efficiently manufacture, market, and sell its products, and foreign currency exchange rates, among other factors that have been and will be outlined in UTMD's public disclosure filings with the SEC.

Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in hundreds of countries around the world as the standard for obtaining optimal long term outcomes for their patients. For more information about Utah Medical Products, Inc., visit UTMD's website at www.utahmed.com.

Utah Medical Products, Inc.

INCOME STATEMENT, First Quarter ended March 31 (in thousands except earnings per share):


1Q 2015 1Q 2014 Percent Change
Net Sales $ 10,233 $ 9,827 +4.1 %
Gross Profit 6,112 6,050 +1.0 %
Operating Income 3,877 3,843 +0.9 %
Income Before Tax 3,668 3,782 (3.0 %)
Net Income 2,667 2,722 (2.0 %)
Earnings Per Share $ 0.706 $ 0.719 (1.8 %)
Shares Outstanding (diluted) 3,776 3,787


BALANCE SHEET

(in thousands) (unaudited)
MAR 31, 2015 (audited)
DEC 31, 2014 (unaudited)
MAR 31, 2014
Assets
Cash & Investments $ 16,157 $ 19,332 $ 15,089
Accounts & Other Receivables, Net 5,013 4,703 5,075
Inventories 4,850 4,872 5,292
Other Current Assets 769 768 876
Total Current Assets 26,789 29,675 26,332
Property & Equipment, Net 7,728 8,236 8,904
Intangible Assets, Net 40,858 43,165 47,658
Total Assets $ 75,375 $ 81,076 $ 82,894
Liabilities & Stockholders' Equity
A/P & Accrued Liabilities $ 5,359 $ 5,077 $ 4,478
Current Portion of Notes Payable -0- 3,894 4,068
Total Current Liabilities 5,359 8,971 8,546
Notes Payable (excluding current portion) -0- 973 4,067
Deferred Tax Liability - Intangibles 5,190 5,581 6,394
Deferred Revenue and Income Taxes 985 995 949
Stockholders' Equity 63,841 64,556 62,938
Total Liabilities & Stockholders' Equity $ 75,375 $ 81,076 $ 82,894


Contact:


Paul Richins
(801) 566-1200

The "Street has UTMD coming in at .91 for the quarter that should be reported on or about May 05, 2014! All post's welcome! The "Good Dr's In"!

Volatile time looks like.

Utah Medical Products, Inc. Reports Financial Performance for Fourth Quarter and Year 2013
GlobeNewswire Utah Medical Products, Inc.
14 hours ago
SALT LAKE CITY, Jan. 30, 2014 (GLOBE NEWSWIRE) -- Utah Medical Products, Inc. (UTMD) concluded another excellent financial year in 2013 under difficult conditions. The results according to Generally Accepted Accounting Principles in the U.S. (US GAAP) are clouded somewhat by a favorable adjustment to UTMD's tax provision, as explained below.

In the fourth calendar quarter (4Q) 2013 and year of 2013, UTMD's changes in U.S. GAAP financial results compared to the same time period in the prior calendar year were as follows:


4Q Year

(October -- December) (January -- December)
Sales: +3% (3%)
Gross Profit: -- (4%)
Operating Income: -- (2%)
Net Income: +54% +12%
Earnings Per Share: +51% +10%
US GAAP earnings per share (EPS) for the 2013 calendar year were $3.02. Year 2012 EPS were $2.74.

Excluding the noncash effects of depreciation, amortization of intangible assets and non-cash stock option expense and asset impairment expense, 2013 consolidated earnings before taxes plus interest expense were $18,136 compared to $18,703 in 2012. Currency amounts in this report are in thousands, except per share amounts and where noted.

As shareholders likely remember, in March 2011 UTMD acquired 100% of the stock of Femcare Holdings Limited in the UK, and its subsidiaries. Included in the purchase price were identifiable intangible assets (IIA) of $38.8 million, almost all of which are being amortized over a fifteen year useful life in operating expenses. This approximately $2.5 million per year amortization expense reduces the income statement tax provision, but is not deductible on the tax return. As a consequence, on the acquisition date, UTMD created a deferred tax liability (DTL) on its balance sheet, using UK tax rates then in effect, which represented the tax impact of the amortization of IIA over the fifteen year life.

In 2013, the government of Great Britain enacted law that substantially reduces corporate income tax rates looking forward. According to U.S. GAAP, the total effect of the tax rate changes on deferred tax balances is recorded as a component of the income tax provision related to continuing operations for the period in which the law is enacted. In other words, the total reduction in the DTL that results from lower future tax rates over the remaining almost 12 years of Femcare IIA amortization, which amounts to $976, reduced UTMD's reported 2013 tax provision and increased reported net profit by the same amount, per U.S. GAAP.

The adjustment only affected UTMD's income tax provision, net income and EPS; not sales, gross profits, operating income or earnings before taxes. Without including the effect of reducing the income tax provision, UTMD's changes in net income and EPS (on a non-GAAP basis) compared to the same time periods in the prior calendar year were as follows:


4Q Year

(October -- December) (January -- December)
Net Income: +10% +3%
Earnings Per Share: +9% +1%
Profitability measures compared to the same time periods in the prior calendar year were as follows:


4Q13 4Q12 2013 2012
Gross Profit Margin (GPM): 59.4% 61.2% 59.9% 60.9%
Operating Profit Margin (OPM): 35.3% 36.3% 36.6% 36.6%
Net Profit Margin (NPM): 34.4% 23.0% 28.2% 24.5%





Without the tax provision adjustment,



Net Profit Margin (Non-GAAP): 24.7% 23.0% 25.8% 24.5%
According to CEO Kevin Cornwell,

"Non-U.S. GAAP earnings per share (EPS) in 2013 without the $976 tax provision adjustment were $2.76, up 1% compared to management's beginning of year projection in its SEC Form 10-K of down 3%. We are pleased that UTMD achieved its financial plan for 2013, with sales slightly lower than projected, but with net income and EPS higher.

Certainly, UTMD shareholders have benefited substantially by the reductions in UK corporate income taxes. We applaud the UK government for its sensible pro-growth, pro-employment tax policy.

We invite shareholders to read UTMD's SEC Form 10-K which will be published by March 17 to obtain more details regarding 2013 performance and management projections for 2014. UTMD's focus remains on creating excellent long term shareholder value through providing highly reliable devices that help clinicians improve care and lower overall health care costs. We appreciate the continued confidence that our shareholders have demonstrated in the Company's prospects for future success."

Sales.

Total consolidated sales were down 2.5% in 2013 compared to 2012. A decline of 2% was projected at the beginning of 2013 due to known distributor overstocking in 2012. The marginal difference can be explained by the strength of the U.S. Dollar (USD) relative to the Great Britain Pound (GBP) and Euro in the first three quarters of 2013, and the significant weakness of the Australian Dollar (AUD) in the last three quarters of the year.

Domestic U.S. sales in 2013 were $18,965 (47% of total sales) compared to $19,961 (48% of total sales) in 2012. In 4Q 2013, domestic U.S. sales were $4,542 (45% of total sales) compared to $4,436 (45% of total sales) in 4Q 2012. International sales in 2013 were $21,528 compared to $21,591 in 2012. In 4Q 2013, international sales were $5,543 compared to $5,397 in 4Q 2012.

The two primary causes of $996 net lower domestic sales were $570 lower sales to Cooper Surgical, Femcare's US distributor of Filshie Clips, as previously anticipated in UTMD's 2012 SEC Form 10-K, and $832 lower sales of neonatal products to domestic users. The decline in sales of domestic neonatal products was due to lower NICU utilization of specialty devices and tightening of compliance under GPO contracts by U.S. hospitals. (In contrast, sales of neonatal products to international customers increased $212 (16%)). Other domestic end user product sales were up $209. Also helping offset the lower domestic Cooper and neonatal product sales were sales of UTMD's components and finished devices for use by other companies (OEM customers) in their products, which were up $178 (11%).

U.S. dollar (USD) denominated sales of devices to international customers by UTMD's Ireland facility (excluding intercompany sales) were up 16% in 2013 compared to 2012, and were down 2% for 4Q 2013 compared to 4Q 2012. In Euro terms, UTMD Ltd (Ireland) 2013 sales were up 13% for the year and down 7% for 4Q. The average currency exchange rate in 2013 was 1.323 USD/Euro compared to 1.289 USD/Euro in 2012. The average currency exchange rate was 1.355 USD/Euro in 4Q 2013 compared to 1.282 USD/Euro in 4Q 2012. Intercompany sales of products manufactured in Ireland increased 33% in 2013 (in Euro terms).

USD denominated sales of devices to domestic and international customers by Femcare Group, Ltd (Femcare-Nikomed Ltd. and Femcare-Australia Ltd.), excluding intercompany sales, were down 7% in 2013 compared to 2012, and were up 8% for 4Q 2013 compared to 4Q 2012. In GBP terms, 2013 Femcare UK subsidiary sales were down 5% for the year and up 14% for 4Q. Sales to Femcare's US distributor, Cooper Surgical Inc., by the Femcare UK subsidiary, as previously described in UTMD's 2012 SEC Form 10-K, were down $570 in 2013. In AUD terms, 2013 Femcare Australia subsidiary sales were down only 1% for the year and for 4Q. Because of the very weak AUD, however, USD denominated Australia sales were down 8% for the year and 12% for 4Q. The average currency exchange rate in 2013 was 0.966 USD/AUD compared to 1.036 USD/AUD in 2012. The average currency exchange rate was 0.930 USD/AUD in 4Q 2013 compared to 1.039 USD/AUD in 4Q 2012. Obviously, because over half of UTMD's consolidated sales are to customers outside of the U.S., fluctuations in currency exchange rates relative to the USD can have a significant effect on consolidated sales reported in USD terms in any particular reporting period.

Gross Profit.

UTMD's 2013 average gross profit margin (GPM) declined more than expected, from 60.9% in 2012 to 59.9% in 2013. About half the decline was anticipated from a less favorable product mix, as growth in sales came from lower profit margin sales in international and domestic OEM sales channels, and revenue declines largely came from domestic direct sales channels with typically higher gross margins. Although raw material costs did experience about 3% inflation, a little more than expected, and fixed labor and overhead costs had to be absorbed on less revenue, also as expected, the difference between management's beginning of year projection of a 60.2% GPM can be explained by a 25% increase in health plan expenses in the U.S. and a 17% increase in Ireland. In USD terms, health plan expenses increased more than $200, representing a half percentage point dilution in the GPM.

Operating Profit.

Operating Profit results from subtracting operating expenses from gross profit. Operating expenses in 2013 were 23.3% of sales compared to 24.3% of sales in 2012. Operating expenses in 4Q 2013 were 24.1% of sales compared to 24.9% of sales in 4Q 2012. By tightly controlling operating expenses, UTMD was able to make up for the decline in GPM and achieve a 2013 operating profit margin (OPM) the same as in 2012. Operating profit in 2013 was $14,828 (36.6% of sales) compared to $15,196 in 2012 (36.6% of sales). In 4Q 2013, UTMD's operating profit was $3,559 (35.3% of sales) compared to 4Q 2012 operating profit of $3,570 (36.3% of sales).

Operating expenses are comprised of general and administrative (G&A) expenses, sales and marketing (S&M) expenses and product development (R&D) expenses. In USD terms, 2013 operating expenses were $9,445 compared to $10,111 in 2012. G&A expenses were $6,164 (15.2% of 2013 sales) compared to $6,836 (16.5% of 2012 sales). G&A expenses in 2012 included U.S. litigation expenses of $170 which did not repeat in 2013. UTMD was also able to substantially reduce G&A expenses in Australia, helped in part by a much weaker AUD, and continued to reduce G&A expenses in the UK. Amortization of the acquired Femcare identifiable intangible assets (IIA) is part of G&A expenses. Amortization of Femcare IIA were 6.2% of sales in both 2013 and 2012. The IIA amortization expense, a noncash expense, of about $2.5 million per year, depending on the USD/GBP exchange rate, will continue until March 2026 (or until the value of remaining IIA becomes impaired). S&M expenses were $2,790 (6.9% of 2013 sales) compared to $2,711 (6.5% of 2012 sales). S&M expenses were up as a result of UTMD being fully staffed in its direct sales force in the UK and Ireland. R&D expenses were $491 (1.2% of 2013 sales) compared to $563 (1.4% of 2012 sales).

EBT.

Earnings Before Tax (EBT) results from subtracting non-operating expenses from operating profit. Non-operating expenses in 2013 were $352 compared to $659 in 2012. The largest component of non-operating expense was interest on UTMD's loans required to finance the 2011 acquisition of Femcare. Interest expense in 2013 was just $438 compared to $652 in 2012 because of UTMD's rate of reduction of its debt balance. 2013 EBT was $14,476 (35.7% of sales) compared to 2012 EBT of $14,537 (35.0% of sales). 2013 EBT and all other income statement measures above the EBT line were unaffected by the reduction in the DTL and income tax provision triggered as a result of the change in UK corporate income tax rates.

Net Profit.

Net profit results from subtracting estimated income taxes from EBT. The consolidated income tax provision rate for 2013 was 21.2% compared to 30.0% in 2012. The lower rate was due to a lower income tax provision rate on UK subsidiary EBT during the year plus the $976 reduction in the provision due to the adjustment in the DTL for future tax periods. The non-U.S. GAAP 2013 provision rate, excluding the $976 reduction, was 28.0%.

UTMD's U.S. GAAP net profit in 2013 was $11,406 (28.2% of consolidated sales) compared to $10,169 in 2012 (24.5% of sales). The non-U.S. GAAP net profit (before applying the $976 tax reduction to the provision due to the reduction in the DTL) was $10,430 (25.8% of sales) compared to $10,169 in 2012.

Despite the headwinds including lower revenues and GPM, UTMD was able to achieve higher net profits in 2013. The higher net profit margin drove UTMD's Return on Shareholder Equity for the year of 2013. Because of a 10% increase in the denominator ($10 million year to prior year increase in Shareholders' Equity), UTMD achieved an ROE (prior to the payment of cash dividends) of 20% compared to 22% in 2012.

Earnings Per Share (EPS).

Outstanding shares at the end of 2013 were 3,743,000 compared to 3,703,000 at the end of 2012. The number of shares used for calculating earnings per share was higher than ending shares because of a time-weighted calculation of average outstanding shares plus dilution from unexercised employee and director options. The total number of outstanding unexercised employee and outside director options at December 31, 2013 was 91,000 shares at an average exercise price of $27.39/ share, including shares awarded but not vested. This compares to 149,500 unexercised option shares outstanding at the end of 2012. The decrease was again due to options exercised by employees after a substantial increase in share price during the year. UTMD's dilution from unexercised option shares added to actual weighted average outstanding shares for purposes of calculating EPS was 43,500 in 4Q 2013 compared to 33,900 in 4Q 2012, and 46,600 for the year 2013 compared to 34,000 in 2012. The increase in dilution was due to a higher average share price in 2013 compared to 2012. No new options were awarded in 2013. In 2012, 13,000 option shares were awarded on October 24, 2012 to 11 employees at an exercise price of $33.30 per share.

UTMD paid $3,675 in cash dividends ($.985/share) to its shareholders in 2013 compared to $3,555 ($.965/share) in 2012. Dividends paid to shareholders during 2013 were 35% of non-GAAP net profits and 36% of non-GAAP EPS (excluding the $976 lower tax provision from the DTL adjustment), and 32% of reported net profits and 33% of reported EPS.

UTMD did not repurchase any of its shares in the open market during 2013. In 2012, the Company repurchased 15,000 shares at $33.57/ share. The Company retains the financial ability for repurchasing its shares when they seem undervalued. The closing share price at the end of 2013 was $57.16, up 59% from the $36.05 closing price at the end of 2012.

Changes in UTMD's Balance Sheet at the end of 2013 from the end of 2012 again represented significant improvement and deleveraging. At the end of 2013, UTMD owned $81 million in total assets including $14 million in cash, offset by about $9 million in bank debt. Intangible assets represented 60% of total assets. Stockholders' Equity was $61 million. In comparison, at the end of 2012, UTMD had $9 million in cash and equivalents as part of $77 million in total assets, and $13 million in bank debt. Intangible assets were 65% of total assets, and Stockholders' Equity was $51 million. The $10 million increase in Shareholders' Equity was achieved in spite of $3.7 million in cash dividends paid to shareholders, which reduces Shareholders' Equity.

Some other highlights regarding changes in UTMD's Balance Sheet during 2013 include:

1) Cash and investments balances increased $5.5 million even though the Company distributed $3.7 million in cash payments to shareholders and reduced loan principal balances in USD terms by $3.9 million.

2) The Deferred Tax Liability resulting from the amortization of Identifiable Intangible Assets from the Femcare acquisition plus other long term liabilities declined $1.7 million.

3) Accounts Receivable over 90 days from date of invoice remained less than 1% of trade receivables.

Financial ratios as of December 31, 2013 which may be of interest to shareholders follow:

1) Current Ratio = 3.2

2) Days in Trade Receivables (based on 4Q sales activity) = 32

3) Average Inventory Turns (based on 4Q CGS) = 3.5

4) 2013 ROE = 20% (prior to payment of dividends)

Investors are cautioned that this press release may contain forward looking statements and that actual events may differ from those projected. Risk factors that could cause results to differ materially from those projected include market acceptance of products, timing of regulatory approval of new products, regulatory intervention in current operations, government health care "reforms", fluctuation in foreign currency exchange rates, the Company's ability to efficiently manufacture, market, and sell its products, among other factors that have been and will be outlined in UTMD's public disclosure filings with the SEC.

Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures, assembles and markets a broad range of disposable and reusable specialty medical devices designed for better health outcomes for patients and their care-providers. For more information about Utah Medical Products, Inc., visit UTMD's website at www.utahmed.com.

Utah Medical Products, Inc.




INCOME STATEMENT, Fourth Quarter (3 months ended December 31)
(in thousands except earnings per share):


4Q 2013 4Q 2012 Percent Change
Net Sales $10,085 $9,832 +2.6%
Gross Profit 5,994 6,021 (0.4%)
Operating Income 3,559 3,570 (0.3%)
Income Before Tax 3,485 3,322 +4.9%
Net Income 3,468 2,259 +53.5%
Earnings Per Share $0.917 $0.606 +51.2%
Shares Outstanding (diluted) 3,784 3,727




INCOME STATEMENT, Year (12 months ended December 31)
(in thousands except earnings per share):


2013 2012 Percent Change
Net Sales $40,493 $41,552 (2.5%)
Gross Profit 24,273 25,307 (4.1%)
Operating Income 14,828 15,196 (2.4%)
Income Before Tax 14,476 14,537 (0.4%)
Net Income 11,406 10,169 +12.2%
Earnings Per Share $3.022 $2.740 +10.3%
Shares Outstanding (diluted) 3,775 3,711

BALANCE SHEET
(in thousands) (audited) (unaudited) (audited)

DEC 31, 2013 SEP 30, 2013 DEC 31, 2012
Assets


Cash & Investments $14,451 $13,922 $8,913
Accounts & Other Receivables, Net 4,388 4,963 4,341
Inventories 4,704 4,660 4,353
Other Current Assets 743 986 928
Total Current Assets 24,286 24,531 18,535
Property & Equipment, Net 8,330 8,279 8,428
Intangible Assets, Net 48,095 47,789 49,972
Total Assets $80,711 $80,599 $76,935




Liabilities & Shareholders' Equity


A/P & Accrued Liabilities $3,559 $5,240 $3,821
Current Portion of Notes Payable 4,052 3,989 4,002
Total Current Liabilities 7,611 9,229 7,823
Notes Payable (excluding current portion) 5,065 5,983 9,003
Other LT Liabilities -- -- 363
Deferred Tax Liability -- Intangibles 6,510 7,433 7,890
Deferred Income Taxes 944 878 884
Stockholders' Equity 60,581 57,076 50,972
Total Liabilities & Shareholders' Equity $80,711 $80,599 $76,935

Contact:
Paul Richins
(801) 566-1200

Utah Medical Products, Inc. Reports Financial Performance for Third Quarter 2013
GlobeNewswirePress Release: Utah Medical Products, Inc. – 13 hours ago..

SALT LAKE CITY, Oct. 24, 2013 (GLOBE NEWSWIRE) -- In the third calendar quarter (3Q) and first nine months (9M) of 2013, Utah Medical Products, Inc.'s (UTMD) changes in financial results compared to the same time period in the prior calendar year were as follows:


3Q
(July --
September) 9M
(January --
September)
Sales: (4%) (4%)
Gross Profit: (8%) (5%)
Operating Income: (7%) (3%)
Net Income: (6%) -
Earnings Per Share: (7%) (1%)

Earnings per share for the most recent twelve months (TTM) were $2.71. Excluding the noncash effects of depreciation, amortization of intangible assets and stock option expense, TTM consolidated earnings before taxes plus interest expense were $18,189. Currency amounts throughout this report are in thousands, except per share amounts and where noted.

UTMD achieved the following profit margins in 3Q 2013 and 9M 2013 compared to 3Q 2012 and 9M 2012:


3Q 2013 3Q 2012 9M 2013 9M 2012

(Jul -- Sep) (Jul -- Sep) (Jan -- Sep) (Jan -- Sep)
Gross Profit Margin (gross profits/ sales): 59.3% 61.7% 60.1% 60.8%
Operating Profit Margin (operating profits/ sales): 36.5% 37.8% 37.1% 36.7%
Net Profit Margin (profit after taxes/ sales): 25.6% 25.9% 26.1% 24.9%

Income Statement Summary.

Due to quarter-to-quarter fluctuation in sales to distributors, the comparison of 2013 quarterly income statement results with the prior year have varied. For example, excluding sales to Cooper Surgical, UTMD's distributor of the Filshie Clip System in the U.S., 3Q 2013 consolidated sales were 1% higher than in 3Q 2012. Excluding, in addition, the negative impact of a stronger U.S. Dollar [USD or $] relative to the Australian Dollar [AUD] and the British Pound [GBP], total consolidated 3Q 2013 sales would have been up 2.4% compared to 3Q 2012 (in contrast to down 4.4%).

Total consolidated sales in 3Q 2013 were consistent with the prior quarter 2Q 2013, but UTMD's gross profit was $100 less due to a less favorable product mix, and a substantial decline in the value of the AUD relative to the USD. A decline in the AUD has a "double-whammy" effect on UTMD's gross profits because USD-denominated sales decline, while variable direct material costs go up because Femcare-Australia is a distributor of UTMD finished devices purchased at fixed USD or British Pound [GBP] prices.

Net income for 9M year-to-date 2013 was slightly higher than for 9M 2012, because operating profit and net income margins were higher than in the prior year.

Shareholders may recall UTMD's guidance for 2013 provided in its year-end December 31, 2012 SEC Form 10-K, as follows:


"In summary, management expects revenues and net income in 2013 to decline about 2%, and gross profit, operating income, EBT and EPS to be down about 3% compared to 2012."

Anticipating that 4Q may be the lowest quarter in 2013 sales, as was the case in 2012, and based on 9M 2013 actual results, the Company now expects consolidated sales and gross profits for the 2013 year to be down 4% to 5% compared to 2012. However, UTMD expects to exceed its 2013 plan for EBT, net income and EPS.

According to CEO Kevin Cornwell,


"After an outstanding financial performance year in 2012, UTMD expected a slightly negative comparison in 2013 particularly because of a difficult environment for medical device companies in the U.S. However, we did not factor in a stronger USD in making our projections. After the first nine months of 2013, although some sales categories and gross profit margins are lagging our beginning projections, profits from excellent operational performance are exceeding plan to the point that UTMD management now expects to be able to match last year's outstanding net income and EPS, instead of being down 3% as initially projected."

Sales. The global consolidated sales comparisons of 3Q 2013 to 3Q 2012 and 9M 2013 to 9M 2012 were substantially affected by the currency exchange impact of a stronger USD relative to the AUD and the GBP. The AUD was 12% weaker in the 3Q 2013 compared to 3Q 2012, and 5.4% weaker for 9M 2013. The GBP was 2% weaker in the 3Q 2013 compared to 3Q 2012 and 2.1% weaker for 9M 2013. If the same AUD and GBP currency exchange rates in 2012 were applied to 3Q and 9M 2013, sales would have been $145 higher in 3Q 2013 and $257 higher in 9M 2013.

In contrast, the Euro was about 5% stronger relative to the USD in 3Q 2013 compared to 3Q 2012, and about 2% stronger for 9M 2013. If Euro currency exchange rates in 2013 had been the same as in 2012, sales would have been about $52 lower in 3Q 2013, and about $57 lower in 9M 2013.

At the beginning of 2013, sales of Femcare's Filshie Clip System devices to Cooper Surgical Inc. for distribution in the U.S. were projected to be $650 lower in 2013. Sales of Femcare's Filshie Clip System devices to Cooper Surgical Inc. were 49% lower ($540) in 3Q 2013 than in 3Q 2012, and 20% lower ($673) in 9M 2013 than in 9M 2012. Filshie Clip System sales to Cooper were 12% of total domestic sales in 3Q 2013 compared to 22% in 3Q 2012. Filshie Clip System sales to Cooper were 19% of total domestic sales in 9M 2013 compared to 22% in 9M 2012. Excluding sales of Femcare's Filshie Clip System devices to Cooper, U.S. domestic sales were 1% lower in 3Q 2013 than in 3Q 2012, and 4% lower in 9M 2013 than in 9M 2012.

Consolidated international sales in 3Q 2013 were up 2% despite the negative impact of a stronger USD. For 9M 2013, international sales were down 1%. International sales were 55% of total consolidated 3Q 2013 sales, and 53% of 9M 2013 sales, compared to 51% in both 3Q 2012 and 9M 2012. UK subsidiary USD-denominated sales were 40% of total international sales in 3Q 2013 compared to 41% in 3Q 2012, and 41% in 9M 2013 compared to 44% in 9M 2012. Australia subsidiary USD-denominated sales were 15% of total international sales in both 3Q 2013 and 9M 2013 compared to 16% in both 3Q 2012 and 9M 2012. Ireland subsidiary USD-denominated sales were 21% of total international sales in 3Q 2013 compared to 16% in 3Q 2012, and 21% in 9M 2013 compared to 17% in 9M 2012.

In product categories, 3Q 2013 blood pressure monitoring device/ components (BPM) sales were up 4%, neonatal device sales were down 1%, gynecology/ electrosurgery device sales were down 7% and obstetrics device sales were down 5%. For 9M 2013 compared to 9M 2012 consolidated global sales in product categories, BPM sales were up 3%, neonatal device sales were down 8%, gynecology/ electrosurgery device sales were down 5% and obstetrics device sales were down 5%.

Gross Profit. UTMD's consolidated gross profit margin (GPM), gross profits divided by sales, was 2.4 percentage points lower in 3Q 2013 than in 3Q 2012. This was due primarily to two factors: 1) an unfavorable product mix, as BPM products, which sales were up, have significantly lower GPMs than the other product categories, which sales were down, and 2) a significantly weaker AUD compared to the USD. As Femcare-Australia purchases its products from UTMD's other subsidiaries in their respective currencies, Femcare-Australia's GPM was down 3.9 percentage points compared to 3Q 2012. UTMD's consolidated GPM for 9M 2013 was 60.1% compared to 60.8% in 9M 2012. This reduced GPM is consistent with management's expectation for 2013 described in the 2012 SEC Form 10-K.

Operating Income. UTMD's 3Q 2013 operating profit margin (OPM) was 1.2 percentage points lower than in 3Q 2012 because of the lower 3Q 2013 GPM. The year-to-date 9M 2013 OPM, however, improved slightly compared to 9M 2012 because of $650 lower operating expenses in 9M 2013 than in 9M 2012. About 89% ($577) of the 9M operating expense decline was in general and administrative (G&A) expenses. Operating expenses in 3Q 2013 were $232 lower than in 3Q 2012. About 94% ($217) of the 3Q decline was in G&A expenses. G&A expenses declined primarily as a result of 1) further consolidation of overhead resources in the UK and AUS, 2) lower litigation expenses, and 3) the weaker GBP and AUD. In contrast to the negative impact on sales, the currency exchange resulting from a stronger USD had a positive impact on consolidated operating expenses (in contrast to cost of goods sold) from UTMD's UK and Australia subsidiaries.

Earnings before Tax (EBT). EBT benefited from lower interest expense as a result of repaying the debt obtained to help acquire Femcare in March 2011. Interest expense in 3Q and 9M 2013 was $104 and $339, respectively, compared to $157 and $516 in the same periods of 2012.

Net Income. UTMD's net income decreased $150 in 3Q 2013, and increased $28 in 9M 2013 compared to the same periods in the prior year. Although diluted by the amortization of intangible assets and interest expense on debt assumed in completing the Femcare acquisition, 3Q 2013 and 9M 2013 net profit margins (NPMs), net income divided by sales, remained excellent at 25.6% and 26.1% for 3Q and 9M 2013, respectively, compared to 25.9% and 24.9% for 3Q 2012 and 9M 2012, respectively. UTMD's consolidated tax provision, as a percentage of EBT, was 28.1% and 27.8% for 3Q and 9M 2013, respectively, compared to 29.3% and 29.5% for 3Q 2012 and 9M 2012. The lower rates in 2013 were due to a corporate income tax rate reduction of one percentage point in the UK, and an increase in profits in Ireland, which has the lowest corporate income tax rate.


Earnings per share (EPS). UTMD's 3Q 2013 EPS decreased 5.0 cents (7%) compared to 3Q 2012 primarily as a result of lower operating income. Shares outstanding used to calculate 3Q 2013 EPS increased to 3,781,389 from 3,725,538 in 3Q 2012. For 9M 2013, EPS decreased 2.9 cents (1%) compared to 9M 2012. Since 9M 2013 net income was slightly higher than in 9M 2012, the 9M 2013 EPS decrease was due solely to an increase in diluted shares outstanding. Diluted shares used to calculate 9M 2013 EPS increased to 3,770,886 from 3,705,992 in 9M 2012. The increases in both periods were due to a much higher average share price in the stock market during 2013 compared to the prior year, and exercises of employee/ director stock options. The Company has not repurchased any of its shares to date in 2013. The same was true in 2012. Notwithstanding, the Company retains the financial ability for repurchasing its shares when they seem undervalued. The closing share price at the end of 3Q 2013 was $59.44 compared to $36.05 at the end of calendar year 2012, and $33.99 at the end of 3Q 2012.

Excluding the noncash effects of depreciation, amortization of intangible assets and stock option expense, 3Q 2013 and 9M 2013 consolidated earnings before taxes plus interest expense were $4,479 and $13,723 respectively.

UTMD's September 30, 2013 balance sheet is substantially stronger than one year earlier. Stockholders' Equity is up $8.4 million (17%) after payment of another $3.6 million in cash dividends to shareholders. Cash balances are up $4.6 million after reduction of loan principal by another $4.9 million. Debt incurred in March 2011 to help finance the Femcare acquisition was $26,934. As of September 30, 2013, the remaining debt balance was $9,972. In ten calendar quarters, UTMD has repaid 63% of the acquisition debt. 9M 2013 capital expenditures were $222, less than depreciation of fixed assets by $237.

Key balance sheet changes as of September 30, 2013 from December 31, 2012 follow:


[Million $$]
Cash & Investments: +5.0
Receivables & Inventory: +0.9
Intangible Assets (net): (2.2)
Notes Payable: (3.0)
Stockholders' Equity: +6.1



Financial ratios as of September 30, 2013 follow:
1) Current Ratio (including the current portion of loans) = 2.7
2) Days in Receivables (based on 3Q sales activity) = 39
3) Average Inventory Turns (based on 3Q CGS) = 3.6
4) Year-to-Date ROE = 20% (prior to dividend payments)
= 13% (after accrual of shareholder dividends)

UTMD's dilution from unexercised option shares added to actual weighted average outstanding shares for purposes of calculating EPS was 46,347 in 3Q 2013 compared to 36,483 in 3Q 2012, and 46,966 in 9M 2013 compared to 33,917 in 9M 2012. The actual number of outstanding shares at the end of 3Q 2013 was 3,737,700 which included additional shares from 3Q 2013 employee option exercises of 9,470 shares. The total number of outstanding unexercised options at September 30, 2013 was 98,100 shares at an average exercise price of $27.36/ share, including shares awarded but not vested. This compares to 169,000 option shares outstanding at the end of 3Q 2012 at an average exercise price of $25.84/ share. No option shares have been awarded to date in 2013.

Risk factors that could cause results to differ materially in future quarters include clinical acceptance of products, timing of regulatory approvals of new products and of distributing existing products in new geographical areas, increased government intervention in the health care marketplace, distribution restrictions by anticompetitive hospital administrative agreements, foreign currency exchange rates, the Company's ability to efficiently manufacture, market, and sell its products globally, among other factors that have been outlined in UTMD's public disclosure filings with the SEC. The SEC Form 10-Q for 3Q 2013 will be filed with the SEC by November 12.

Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in hundreds of countries around the world as the standard for obtaining optimal long term outcomes for their patients. For more information about Utah Medical Products, Inc., visit UTMD's website at www.utahmed.com.

Utah Medical Products, Inc.
INCOME STATEMENT, Third Quarter (3 months ended September 30)
(in thousands except earnings per share):






3Q 2013 3Q 2012 Percent Change
Net Sales $10,032 $10,489 (4.4%)
Gross Profit 5,949 6,477 (8.1%)
Operating Income 3,665 3,960 (7.4%)
Income Before Tax 3,577 3,849 (7.1%)
Net Income 2,571 2,721 (5.5%)
Earnings Per Share $0.68 $0.73 (6.9%)
Shares Outstanding (diluted) 3,781 3,726






INCOME STATEMENT, Nine Months (9 months ended September 30)
(in thousands except earnings per share):






9M 2013 9M 2012 Percent Change
Net Sales $30,408 $31,719 (4.1%)
Gross Profit 18,279 19,286 (5.2%)
Operating Income 11,269 11,627 (3.1%)
Income Before Tax 10,991 11,215 (2.0%)
Net Income 7,938 7,910 +0.4%
Earnings Per Share $2.11 $2.13 (1.4%)
Shares Outstanding (diluted) 3,771 3,706








BALANCE SHEET




(in thousands) (unaudited) (unaudited) (audited) (unaudited)

SEP 30, 2013 JUN 30, 2013 DEC 31, 2012 SEP 30, 2012
Assets




Cash & Investments $13,922 $11,437 $8,913 $9,369
Accounts & Other Receivables, Net 4,963 5,673 4,341 5,037
Inventories 4,660 4,367 4,353 4,707
Other Current Assets 986 812 928 944
Total Current Assets 24,531 22,289 18,535 20,057
Property & Equipment, Net 8,279 8,155 8,428 8,449
Intangible Assets, Net 47,789 45,985 49,972 50,297
Total Assets $80,599 $76,429 $76,935 $78,803






Liabilities & Shareholders' Equity




A/P & Accrued Liabilities $5,240 $4,773 $3,821 $5,965
Current Portion of Notes Payable 3,989 3,834 4,002 5,450
Total Current Liabilities 9,229 8,607 7,823 11,415
Notes Payable (excluding current portion) 5,983 6,709 9,003 9,415
Other LT Liabilities -- -- 363 450
Deferred Tax Liability -- Intangible 7,433 7,583 7,890 8,053
Deferred Income Taxes 878 889 884 760
Shareholders' Equity 57,076 52,641 50,972 48,710
Total Liabilities & Shareholders' Equity $80,599 $76,429 $76,935 $78,803


.
.
Contact:.
.
Paul Richins
(801) 566-1200

Utah Medical Products, Inc. Reports Financial Performance for Second Quarter 2013
GlobeNewswirePress Release: Utah Medical Products, Inc. – Thu, Jul 25, 2013 9:00 AM EDT..

SALT LAKE CITY, July 25, 2013 (GLOBE NEWSWIRE) -- In the second calendar quarter (2Q) and first half (1H) of 2013, Utah Medical Products, Inc.'s (UTMD) changes in financial results compared to the same time period in the prior calendar year were as follows:


2Q 1H

(April -- June) (January -- June)
Sales: - (4%)
Gross Profit: - (4%)
Operating Income: + 5% (1%)
Net Income: + 10% + 3%
Earnings Per Share: + 8% + 1%

Earnings per share for the most recent twelve months (TTM) were $2.76. Excluding the noncash effects of depreciation, amortization of intangible assets and stock option expense, TTM consolidated earnings before taxes plus interest expense were $18,544. Currency amounts throughout this report are in thousands, except per share amounts and where noted.

UTMD achieved the following profit margins in 2Q 2013 and 1H 2013 compared to 2Q 2012 and 1H 2012:


2Q 2013 2Q 2012 1H 2013 1H 2012

(Apr -- Jun) (Apr -- Jun) (Jan -- Jun) (Jan -- Jun)
Gross Profit Margin (gross profits/ sales): 60.5% 60.6% 60.5% 60.3%
Operating Profit Margin (operating profits/ sales): 37.1% 35.4% 37.3% 36.1%
Net Profit Margin (profit after taxes/ sales): 26.3% 24.0% 26.3% 24.4%

Income Statement Summary.

Due to distributor overstocking in 1Q 2012, the comparison of 2013 income statement results with the prior year started off negative, as sales, gross profits, operating income, net income and earnings per share were down 7%, 7%, 5%, 2% and 4%, respectively, in 1Q 2013 compared to 1Q 2012, as reported on April 25, 2013.

Performance in 2Q 2013 was consistent in sales and gross profits with 2Q 2012, with better operating income, net income and eps. As a result, the comparison of 1H 2013 with 1H 2012 remains negative, although less so than after 1Q.

As an alternative comparison, the following table compares 1H 2013 quarterly average income statement results with the average quarterly performance for the entire year of 2012:



1H 2013 2012 Year


Quarterly Average Quarterly Average
Sales: (2%) $ 10,188 $ 10,388
Gross Profit: (3%) 6,165 6,327
Operating Income: -- 3,802 3,799
Net Income: +6% 2,684 2,542
Earnings Per Share: +4% .713 .685

Shareholders may recall UTMD's guidance for 2013 provided in its year-end December 31, 2012 SEC Form 10-K, as follows:


"In summary, management expects revenues and net income in 2013 to decline about 2%, and gross profit, operating income, EBT and eps to be down about 3% compared to 2012."

Based on 1H 2013 actual results, the Company is on its plan for sales and gross profits, and exceeding its plan for other profitability measures.

According to CEO Kevin Cornwell,


"After an outstanding financial performance year in 2012, UTMD expected a slightly negative comparison in 2013 in a difficult economic environment for medical device companies. After the first half of 2013, although some sales categories are lagging our expectations, profits from excellent operational performance are exceeding expectations to the point that UTMD may be able to match last year's eps instead of being down 3%, as previously projected."

Sales. The global consolidated sales comparisons of 2Q 2013 to 2Q 2012, and 1H 2013 to 1H 2012, were negatively affected by the currency exchange impact of a stronger U.S. Dollar (USD or $) relative to the British Pound (GBP) and the Australian Dollar (AUD). The GBP was about 3% weaker in the 2Q and about 2% weaker for the 1H. The AUD was about 1% weaker in the 2Q and about 2% weaker for the 1H. In contrast, the Euro was about 2% stronger in the 2Q and about the same for the 1H. If currency exchange rates in 2013 had been the same as in 2012, consolidated sales would have been about $44 higher in 2Q 2013, and about $103 higher in 1H 2013.

U.S. domestic sales were 2% higher in 2Q 2013 than in 2Q 2012, and 5% lower in 1H 2013 than in 1H 2012. Sales of Femcare's Filshie Clip System devices to Cooper Surgical Inc. for distribution in the U.S. were 97% higher in 2Q 2013 compared to 2Q 2012, and 6% lower in 1H 2013 compared to 1H 2012. Filshie Clip System sales to Cooper were 22% of total domestic sales in 2Q 2013 compared to 11% in 2Q 2012. Filshie Clip System sales to Cooper were 22% of total domestic sales in both 1H 2013 and 1H 2012.

International sales in 2Q 2013 were down 2%, and in 1H 2013 were down 3%. International sales were 51% of total consolidated 2Q 2013 sales, and 52% of 1H 2013 sales. UK subsidiary sales were 40% of total international sales in 2Q 2013, and 41% in 1H 2013. Australia subsidiary sales were 16% of total international sales in 2Q 2013, and 15% of total international sales in 1H 2013. Ireland subsidiary sales were 21% of total international sales in 2Q 2013, and 22% in 1H 2013.

In product categories, 2Q 2013 blood pressure monitoring device/ components (BPM) sales were up 1%, neonatal device sales were down 20%, gynecology/ electrosurgery device sales were up 6% and obstetrics device sales were down 5%. For 1H 2013 compared to 1H 2012 global sales in product categories, BPM sales were up 3%, neonatal device sales were down 12%, gynecology/ electrosurgery device sales were down 4% and obstetrics device sales were down 5%.

Gross Profit. UTMD's consolidated gross profit margin (GPM), gross profits divided by sales, was 60.5% in both 2Q 2013 and 1H 2013 compared to 60.6% in 2Q 2012 and 60.3% in 1H 2012.

Operating Income. UTMD's 2Q and 1H 2013 operating profit margins (OPMs), operating income divided by sales, were 37.1% and 37.3% respectively, compared to 35.4% and 36.1% in the same periods of 2012. Operating expenses in 2Q 2013 were $186 lower than in 2Q 2012. About 72% of the $186 2Q decline was in general and administrative (G&A) expenses as a result of further consolidation of overhead resources in the UK and AUS, combined with the weaker GBP and AUD. In contrast to the negative impact on sales, the currency exchange resulting from a stronger USD had a positive impact on consolidating operating expenses from UTMD's UK and Australia subsidiaries. In summary, the higher OPMs in 2013 were due to 1) GPM consistent with the prior year, and 2) improved productivity of operating resources in the UK and AUS.

Earnings before Tax (EBT). Compared to 2Q 2012, 2Q 2013 EBT improved not only as a result of $163 higher operating income (despite slightly lower sales), but also from $58 lower interest expense as a result of repaying the debt obtained to help acquire Femcare in March 2011. Interest expense in 2Q and 1H 2013 was $113 and $235, respectively, compared to $171 and $360 in the same periods of 2012. In summary, 2Q and 1H 2013 EBT margins were 36.3% and 36.4%, respectively, compared to 34.2% and 34.7% in the same periods of 2012.

Net Income. UTMD's net income increased 10% in 2Q 2013 and 3% in 1H 2013 compared to the same periods in the prior year. Although diluted by the amortization of intangible assets and interest expense on debt assumed in completing the Femcare acquisition, 2Q 2013 and 1H 2013 net profit margins (NPMs), net income divided by sales, remained excellent at 26.3% for both periods compared to 24.0% and 24.4% for 2Q 2012 and 1H 2012, respectively. As of April 1, 2013, the UK corporate income tax rate was reduced to 23% from 24%.

Earnings per share (EPS). 2Q 2013 EPS increased 5.1 cents (8%) compared to 2Q 2012 as a result of the improved profit margins and lower corporate income tax rate in the UK. For 1H 2013, EPS increased 2.1 cents (1%) compared to 1H 2012. Counteracting the profit increase, diluted shares outstanding used to calculate 2Q 2013 EPS increased to 3,769,588 from 3,710,827 in 2Q 2012. Diluted shares used to calculate 1H 2013 EPS increased to 3,763,834 from 3,693,590 in 1H 2012. The increases were due to a much higher average share price in the stock market during 2013 compared to the prior year, and exercises of employee/ director options. The Company has not repurchased any of its shares to date in 2013. The same was true in 2012. Notwithstanding, the Company retains the financial ability for repurchasing its shares when they seem undervalued. The closing share price at the end of 2Q 2013 was $54.30 compared to $36.05 at the end of calendar year 2012, and $33.53 at the end of 2Q 2012.

Excluding the noncash effects of depreciation, amortization of intangible assets and stock option expense, 2Q 2013 and 1H 2013 consolidated earnings before taxes plus interest expense were $4,535 and $9,245 respectively.

UTMD's June 30, 2013 balance sheet compared with its December 31, 2012 balance sheet demonstrates continued improvement. Debt incurred in March 2011 to help finance the Femcare acquisition was $26,934. As of June 30, 2013, the remaining debt balance was $10,543. In just nine calendar quarters, UTMD has repaid 61% of the acquisition debt. 1H 2013 capital expenditures were $111, less than depreciation of fixed assets by $197.

Key balance sheet changes as of June 30, 2013 from the end of 2012 follow:


[Million $$]
Cash & Investments: + 2.5
Receivables & Inventory: + 1.3
Intangible Assets (net): (4.0)
Total Current Liabilities: + 0.8
Notes Payable: (2.5)
Shareholders' Equity: + 1.7

Financial ratios as of June 30, 2013 follow:

1) Current Ratio (including the current portion of loans) = 2.6

2) Days in Receivables (based on 2Q sales activity) = 46

3) Average Inventory Turns (based on 2Q CGS) = 3.6

4) Year-to-Date ROE = 21% (prior to dividend payments)


= 14% (after accrual of shareholder dividends)

UTMD's dilution from unexercised option shares added to actual weighted average outstanding shares for purposes of calculating eps was 44,511 in 2Q 2013 compared to 32,825 in 2Q 2012, and 45,567 in 1H 2013 compared to 30,099 in 1H 2012. The actual number of outstanding shares at the end of 2Q 2013 was 3,728,300 which included 2Q 2013 employee option exercises of 6,400 shares. The total number of outstanding unexercised options at June 30, 2013 was 109,400 shares at an average exercise price of $27.01/ share, including shares awarded but not vested. This compares to 183,500 option shares outstanding at the end of 2Q 2012 at an average exercise price of $25.89/ share. No option shares have been awarded to date in 2013.

Risk factors that could cause results to differ materially in future quarters include clinical acceptance of products, timing of regulatory approvals of new products and of distributing existing products in new geographical areas, government intervention in the health care marketplace, distribution restrictions by anticompetitive hospital administrative agreements, foreign currency exchange rates, the Company's ability to efficiently manufacture, market, and sell its products globally, among other factors that have been outlined in UTMD's public disclosure filings with the SEC. The SEC Form 10-Q for 2Q 2013 will be filed with the SEC by August 9.

Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in hundreds of countries around the world as the standard for obtaining optimal long term outcomes for their patients. For more information about Utah Medical Products, Inc., visit UTMD's website at www.utahmed.com.

Utah Medical Products, Inc.
INCOME STATEMENT, Second Quarter (3 months ended June 30)
(in thousands except earnings per share):






2Q 2013 2Q 2012 Percent Change
Net Sales $10,002 $10,025 (0.2%)
Gross Profit 6,048 6,071 (0.4%)
Operating Income 3,715 3,552 + 4.6%
Income Before Tax 3,627 3,430 + 5.7%
Net Income 2,632 2,401 + 9.6%
Earnings Per Share $0.698 $0.647 + 7.9%
Shares Outstanding (diluted) 3,770 3,711






INCOME STATEMENT, First Half (6 months ended June 30)
(in thousands except earnings per share):






1H 2013 1H 2012 Percent Change
Net Sales $20,376 $21,230 (4.0%)
Gross Profit 12,329 12,809 (3.7%)
Operating Income 7,605 7,667 (0.8%)
Income Before Tax 7,414 7,367 + 0.6%
Net Income 5,368 5,190 + 3.4%
Earnings Per Share $1.426 $1.405 + 1.5%
Shares Outstanding (diluted) 3,764 3,694


BALANCE SHEET






(in thousands) (unaudited) (unaudited) (audited) (unaudited)

JUN 30, 2013 MAR 31, 2013 DEC 31, 2012 JUN 30, 2012
Assets




Cash & Investments $11,437 $10,918 $8,913 $7,984
Accounts & Other Receivables, Net 5,673 5,363 4,341 5,089
Inventories 4,367 4,406 4,353 4,834
Other Current Assets 812 910 928 745
Total Current Assets 22,289 21,597 18,535 18,652
Property & Equipment, Net 8,155 8,203 8,428 8,532
Intangible Assets, Net 45,985 46,562 49,972 49,696
Total Assets $76,429 $76,362 $76,935 $76,880






Liabilities & Shareholders' Equity




A/P & Accrued Liabilities $4,773 $5,193 $3,821 $5,345
Current Portion of Notes Payable 3,834 3,831 4,002 5,406
Total Current Liabilities 8,607 9,024 7,823 10,751
Notes Payable (excluding current portion) 6,709 7,663 9,003 11,154
Other LT Liabilities -- 339 363 438
Deferred Tax Liability -- Intangible 7,583 7,733 7,890 8,216
Deferred Revenue and Income Taxes 889 887 884 773
Shareholders' Equity 52,641 50,716 50,972 45,548
Total Liabilities & Shareholders' Equity $76,429 $76,362 $76,935 $76,880


.
.
Contact:.
.
Paul Richins
(801) 566-1200

..

Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2013
Press Release: Utah Medical Products, Inc. – Thu, Apr 25, 2013 9:00 AM EDT.. .
.


Email






Print
...

.
.

RELATED QUOTES.
.



Symbol

Price

Change




UTMD

44.88

-0.68





.
.
..

.
.

SALT LAKE CITY, April 25, 2013 (GLOBE NEWSWIRE) -- In the first calendar quarter (1Q) of 2013, Utah Medical Products, Inc. (UTMD) achieved financial results on track to meet its previously announced full year goals. Compared to the same quarter in the prior year, profit margins improved in all income statement categories, as follows:






1Q 2013
(JAN -- MAR)

1Q 2012
(JAN -- MAR)



Gross Profit Margin (gross profits/ sales):

60.5%

60.1%



Operating Profit Margin (operating profits/ sales):

37.5%

36.7%



EBT Margin (profits before income taxes/ sales):

36.5%

35.1%



Net Profit Margin (profit after taxes/ sales):

26.4%

24.9%


UTMD's Operating Profit Margin (OPM) improved despite the new Medical Device Excise Tax (MDET), imposed as a component of the Patient Protection and Affordable Care Act (Obamacare). Without the tax, levied as 2.3% of domestic sales of medical devices, UTMD's consolidated 1Q 2013 OPM would have been 38.2%.

As shareholders may recall, in the same 1Q period of the prior year of 2012, a couple of UTMD's largest OEM/international distributor customers purchased substantially more than their quarterly averages. As a result, the following is the comparison of 1Q 2013 to 1Q 2012:



Sales:




(7%)



Gross Profit:




(7%)



Operating Income:




(5%)



Net Income:




(2%)



Earnings Per Share:




(4%)


As UTMD states in its quarterly SEC Form 10-Q disclosures, 'Because of the relatively short span of time, results for any given three month period in comparison with any previous three month period may not be indicative of comparative results for the year as a whole.'

Currency amounts throughout this report are in thousands, except per share amounts and where noted.

According to CEO Kevin Cornwell, "I believe the year has started well; better than expected with respect to profit margins. We expected that the comparison of first quarter 2013 income statement results with first quarter 2012, our best quarter during last year, may not look particularly good to investors given the very high standard of performance that UTMD achieved last year. However, after the first quarter results, we remain confident that we can achieve or exceed the goals we set for the full year of 2013 as described in the 2012 SEC Form 10-K."

As an alternative comparison, the following table compares 1Q 2013 income statement results with the average quarterly performance for the entire year of 2012:









1Q 2013

2012












Quarterly Average



Sales:

--

$ 10,374

$ 10,388



Gross Profit:

(1%)

6,281

6,327



Operating Income:

+2%

3,889

3,799



Net Income:

+8%

2,735

2,542



Earnings Per Share:

+6%

.728

.685


Sales.

Most of the 1Q 2013 sales decline compared to 1Q 2012 was due to the expected $656 decline in Filshie Clip shipments by UTMD's Femcare UK subsidiary to its U.S. distributor, Cooper Surgical, due to overstocking in the prior year. This accounted for 79% of UTMD's total consolidated sales decline (6% points of the 7% decline).

International sales were down $213 (2% of total 1Q 2012 sales). This was primarily due to $296 lower sales to UTMD's China distributor of its blood pressure monitoring devices, which also overstocked in 1Q 2012. UTMD's Ireland subsidiary shipments were up 8% in Euro terms. UTMD's UK subsidiary shipments, which included the Filshie Clip shipments to Cooper Surgical, were down 19% in GBP terms. UTMD's Australia subsidiary shipments were down 14% in AUD terms. When translating 1Q 2013 foreign currency sales into U.S. Dollars (USD), the same foreign currency sales were about 2% lower when expressed in USD than in 2012 due to a stronger USD.

Domestic sales in 1Q 2013, excluding sales to Cooper Surgical, were up 1% compared to 1Q 2012. It appears that the previous decline in hospital utilization rates of specialty devices may have stabilized.



Gross Profit.

UTMD's 1Q 2013 gross profit margin (GPM), gross profits divided by sales, was slightly higher than 1Q 2012 and slightly higher than the GPM projected for the full year of 2013 in UTMD's 2012 SEC Form 10-K, but slightly lower than the average GPM for the full previous year of 2012 for the reasons described in the SEC 10-K.

Operating Income.

Operating expenses, comprised of G&A, S&M and R&D expenses, were $2,392 in 1Q 2013 (23.1% of sales), compared to $2,623 in 1Q 2012 (23.4% of sales), despite $75 added to 1Q 2013 operating expenses for the Obamacare MDET that weren't part of 2012 operating expenses. In financial projections for 2013 included in UTMD's 2012 SEC Form 10-K, management included the MDET in non-operating expenses. The change in classification from non-operating to operating expenses, more specifically S&M expenses, was the result of a recommendation by UTMD's independent accounting firm. The MDET paid in 1Q 2013 was consistent with UTMD's expectation.

Lower consolidated operating expenses in USD terms resulted in part from foreign subsidiary operating expenses reduced by about 2% as a result of a stronger USD. G&A expenses were $1,600 (15.4% of sales) in 1Q 2013 compared to $1,827 (16.3% of sales) in 1Q 2012. The G&A expenses in 1Q 2013 included $625 (6.0% of sales) of non-cash expense from the amortization of identifiable intangible assets resulting from the Femcare acquisition, which were $635 (5.7% of sales) in 1Q 2012. In addition to the reduction in foreign operating expense due to a stronger USD, lower G&A expenses were primarily the result of 1) $100 lower litigation expense in the U.S.; 2) $48 lower UK expense from the termination of leases and rents incurred in the prior year, and a foreign currency exchange gain on accounts receivable; and 3) $18 in lower variable expenses in Australia related to lower sales activity, and a reclassification of $22 Australia freight expense included in G&A in 2012 to S&M expense in 2013.

S&M expenses were $669 (6.4% of sales) in 1Q 2013 compared to $651 (5.8% of sales) in 1Q 2012. S&M expenses in 1Q 2013 included $75 MDET. R&D expenses were $123 (1.2% of sales) in 1Q 2013 compared to $146 (1.3% of sales) in 1Q 2012.

UTMD's 1Q 2013 operating profit margin (OPM), operating income divided by sales, improved to 37.5% compared to 36.7% in 1Q 2012 as a result of the improvement in GPM combined with $232 lower operating expenses described above.

Income Before Tax.

Income before taxes (EBT) result from subtracting UTMD's net non-operating expense (NOE) from its operating income. NOE includes loan interest and bank fees minus non-operating income from rent of underutilized property, investment income and royalties received from licensing the Company's technology. NOE in 1Q 2013 was $102 compared to $178 in 1Q 2012. The difference was primarily due to interest on loans obtained to help finance the acquisition of Femcare. 1Q 2013 interest expense was $122. 1Q 2012 interest expense was $189. Consolidated EBT was $3,787 in 1Q 2013 compared to $3,937 in 1Q 2012. The EBT of UTMD Ltd. (Ireland) was EURO227 in 1Q 2013 compared to EURO122 in 1Q 2012. The EBT of Femcare (Femcare-Nikomed, Ltd., UK and Femcare Australia) was [Pounds]1,030 in 1Q 2013 compared to [Pounds]1,277 in 1Q 2012. The respective EBT margins (EBT divided by sales) of UTMD Ltd. (Ireland) were 24.5% in 1Q 2013 and 14.3% in 1Q 2012. The respective EBT margins of Femcare were 36.7% in 1Q 2013 and 37.5% in 1Q 2012. Excluding the noncash effects of depreciation, amortization of intangible assets, write-off of impaired assets and stock option expense, 1Q 2013 and most recent twelve months consolidated EBT plus interest expense were $4,710 and $18,447, respectively.

Net Income.

UTMD's net profit margin (NPM), net income divided by sales, was 26.4% in 1Q 2013 compared to 24.9% in 1Q 2012. The improvement in 1Q 2013 NPM compared to the prior period was due to the improvement in OPMs described above, progressively lower interest expense as UTMD repaid debt it obtained when financing the Femcare acquisition, greater profit in Ireland, the lowest taxed sovereignty, and a lower corporate income tax rate in the UK. The average consolidated income tax provisions (as a % of EBT) in 1Q 2013 and 1Q 2012 were 27.8% and 29.2%, respectively.

UTMD's combined state and federal income tax rate in the U.S. after all allowable deductions was 33.1% in 1Q 2013 compared to 34.6% in 1Q 2012. The corporate income tax rate in the UK was 24% in 1Q 2013 compared to 26% in 1Q 2012. As of April 1, 2013, the UK corporate tax rate was reduced again, from 24% to 23%, which will further benefit UTMD's NPM during the remainder of 2013. The income tax rate in Australia has been and remains 30%. UTMD Ltd (Ireland) tax provision rate was 13.2% in 1Q 2013.

Earnings per share (EPS).

Earnings per share for the most recent twelve months were $2.71. EPS in 1Q 2013 decreased more than the percent decrease in net income due to the exercise of employee options and the higher dilution factor applied to unexercised options as a result of a much higher average market price of UTMD stock. Diluted shares used to calculate EPS increased to 3,756,900 in 1Q 2013 from 3,674,900 in 1Q 2012. The number of shares added as a dilution factor in 1Q 2013 was 45,500 compared to 25,900 in 1Q 2012.

Outstanding shares at the end of 1Q 2013 were 3,722,100. The number of shares used for calculating earnings per share was higher than ending shares because of a time-weighted calculation of average outstanding shares plus dilution from unexercised employee and director options. The total number of outstanding unexercised employee and outside director options at March 31, 2013 was 116,300 shares at an average exercise price of $27.04/ share, including shares awarded but not vested. This compares to 202,000 unexercised option shares outstanding at March 31, 2012 at an average exercise price of $25.75/ share.

During both 1Q 2013 and 1Q 2012, UTMD did not repurchase its shares in the open market. The Company retains the financial ability for repurchasing its shares when they seem undervalued. The closing share price at the end of 1Q 2013 was $48.77 compared to $36.05 at the end of calendar year 2012, and $31.10 at the end of 1Q 2012.

Balance Sheet.

There were a few significant changes in UTMD's Balance Sheet at March 31, 2013 from March 31, 2012. From a year earlier, cash and investments increased $2.7 million so that the $10.9 million balance of cash and investments at March 31, 2013 was within $0.6 million of UTMD's bank debt balance of $11.5 million remaining from borrowing $26.9 million to help finance the acquisition of the Femcare Group, Ltd. In the two years following the Femcare acquisition, UTMD has repaid 57% of the loan provided by JP Morgan Chase. Over the most recent one year period, net intangible assets declined $4.6 million and debt principal declined $8.0 million. Stockholders' Equity increased $6.2 million after cash payments of dividends to shareholders of $3.6 million and share repurchases of $0.5 million (which reduce Stockholders' Equity).

Financial ratios as of March 31, 2013 which may be of interest to shareholders follow:

1) Current Ratio = 2.4

2) Days in Trade Receivables (based on 1Q 2013 sales activity) = 41

3) Average Inventory Turns (based on 1Q 2013 CGS) = 3.7

4) 2013 YTD ROE = 22%

Investors are cautioned that this press release contains forward looking statements and that actual events may differ from those projected. Risk factors that could cause results to differ materially from those projected include market acceptance of products, timing of regulatory approval of new products, regulatory intervention in current operations, government healthcare "reforms", the Company's ability to efficiently manufacture, market, and sell its products, among other factors that have been and will be outlined in UTMD's public disclosure filings with the SEC.

Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in hundreds of countries around the world as the standard for obtaining optimal long term outcomes for their patients. For more information about Utah Medical Products, Inc., visit UTMD's website at www.utahmed.com.



Utah Medical Products, Inc.

















INCOME STATEMENT, First Quarter ended March 31 (in thousands except earnings per share):






1Q 2013

1Q 2012

Percent Change



Net Sales

$10,374

$11,206

(7.4%)



Gross Profit

6,281

6,738

(6.8%)



Operating Income

3,889

4,115

(5.5%)



Income Before Tax

3,787

3,937

(3.8%)



Net Income

2,735

2,789

(1.9%)



Earnings Per Share

$0.728

$0.759

(4.1%)



Shares Outstanding (diluted)

3,757

3,675




















BALANCE SHEET












(in thousands)

(unaudited)

(audited)

(unaudited)






March 31, 2013

December 31, 2012

March 31, 2012



Assets












Cash & Investments

$10,918

$8,913

$8,239



Accounts & Other Receivables, Net

5,363

4,341

6,065



Inventories

4,406

4,353

4,835



Other Current Assets

910

929

853



Total Current Assets

21,597

18,535

19,992



Property & Equipment, Net

8,203

8,428

8,813



Intangible Assets, Net

46,562

49,972

51,162



Total Assets

$76,362

$76,935

$79,967



Liabilities & Stockholders' Equity












A/P & Accrued Liabilities

$5,193

$3,821

$6,317



Current Portion of Notes Payable

3,831

4,001

5,485



Total Current Liabilities

9,024

7,823

11,802



Notes Payable (excluding current portion)

7,663

9,003

14,042



Other LT Liabilities

339

363

446



Deferred Tax Liability -- Intangibles

7,733

7,889

8,379



Deferred Revenue and Income Taxes

887

884

768



Stockholders' Equity

50,716

50,972

44,530



Total Liabilities & Stockholders' Equity

$76,362

$76,935

$79,967



.
.
Contact:.
.
Paul Richins(801) 566-1200. ...

http://finance.yahoo.com/news/utah-medical-products-inc-reports-130000597.html

It's significantly "Under-Valued" at the current levels that it trades at. Stay long!

Top trend line here. You sell long?

More like stirring up a little "Dust"!

Alerted for ~ Monday now.. $UTMD ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $UTMD ~ Earnings expected on Monday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=UTMD&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=UTMD&p=W&b=3&g=0&id=p54550695994



~ Google Finance: http://www.google.com/finance?q=UTMD
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=UTMD#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=UTMD+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=UTMD
Finviz: http://finviz.com/quote.ashx?t=UTMD
~ BusyStock: http://busystock.com/i.php?s=UTMD&v=2


<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=UTMD >>>>>>



http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

Thanks, .24 not to shabby.. They are trying to compete with big oil it seems.

http://finance.yahoo.com/news/Utah-Medical-Products-Inc-pz-191658974.html?x=0

~ $UTMD ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $UTMD ~ Earnings expected on Tuesday *
This Week In Earnings: Earnings are coming or are already posted! This is what the charts look like! If you play the earnings these posts can be very helpful to you!
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=UTMD&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=UTMD&p=W&b=3&g=0&id=p54550695994



~ Barchart: http://barchart.com/quotes/stocks/UTMD?
~ OTC Markets: http://www.otcmarkets.com/stock/UTMD/company-info
~ Google Finance: http://www.google.com/finance?q=UTMD
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=UTMD#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=UTMD+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=UTMD
Finviz: http://finviz.com/quote.ashx?t=UTMD
~ BusyStock: http://busystock.com/i.php?s=UTMD&v=2
~ CandlestickChart: http://www.candlestickchart.com/cgi/chart.cgi?symbol=UTMD&exchange=US
~ Investorshub Trades: http://ih.advfn.com/p.php?pid=trades&symbol=UTMD
~ Investorshub Board Search: http://investorshub.advfn.com/boards/getboards.aspx?searchstr=UTMD
~ Investorshub PostStream Search: http://investorshub.advfn.com/boards/poststream.aspx?ticker=UTMD
~ Investorshub Goodies Search: http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18582&srchyr=2011&SearchStr=UTMD
~ Investorshub Message Search: http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=UTMD
~ MarketWatch: http://www.marketwatch.com/investing/stock/UTMD/profile
~ E-Zone Chart: http://www.windchart.com/ezone/signals/?symbol=UTMD
~ 5-Min Wind: http://www.windchart.com/stockta/analysis?symbol=UTMD
~ 10-Min Wind: http://www.windchart.com/stockta/analysis?symbol=UTMD&size=l&frequency=10&color=g
~ 30-Min Wind: http://www.windchart.com/stockta/analysis?symbol=UTMD&size=l&frequency=30&color=g
~ 60-Min Wind: http://www.windchart.com/stockta/analysis?symbol=UTMD&size=l&frequency=60&color=g


http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

http://finance.yahoo.com/news/Utah-Medical-Products-Inc-pz-81896812.html?x=0

http://finance.yahoo.com/news/National-Technical-Systems-prnews-494112099.html?x=0

All posts welcome as the "Good Dr's In"!